100+ Vendors
50+ Compounds
100+ Vendor COAs
Price/MG Comparison
Exclusive Coupons
BPC-157

Research peptide

BPC-157

PreclinicalHealing & RecoveryBPC Cytoprotective PathwayInjury RecoveryGut Health

From

$12.41

Vendors

22

Lab tested

19 COAs

Key benefits

  • Faster tendon healing in rats
  • Protects the gut lining in animals
  • Supports new blood vessel growth
  • Early human pain relief reports

BPC-157 is a 15-amino-acid peptide first described from gastric juice. Most of the published work is preclinical, with studies covering tendon, muscle, gastrointestinal, vascular, and other injury models.

Researchers have looked at several signaling pathways, including VEGFR2, nitric oxide, Akt-eNOS, and ERK1/2. Other work has focused on angiogenesis, fibroblast activity, endothelial responses, and inflammation.

Human data are still sparse. Small studies have looked at knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics, but the number of human studies remains small and larger controlled trials are not available.

Typical dose

250-500mcg

Once or twice daily

Route

Subcutaneous

Can be administered once or twice daily. For localized injury, inject near the site. For systemic effects, subcutaneous abdomen injection is common.

Cycle

4–8 weeks

Typical duration

Storage

2-6°C

Follow vendor guidance

Marketplace

Compare all BPC-157 vendors

Prices per size, coupon codes, lab reports and shipping.

22 offers

What is BPC-157?

BPC-157 is a 15-amino-acid-long peptide, also known as a pentadecapeptide. Its amino acid sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val The peptide is often the subject of conversations, as experimental investigations have explored it across multiple tissue and injury types.

BPC-157

Compound

BPC-157

What Is BPC-157 Used For?

BPC-157 has been primarily explored in preclinical tissue-repair models, such as tendon, ligament, muscle, GI, and vascular injury. Inflammatory responses, blood-vessel signaling, oxidative stress, and ischemia-reperfusion injury have also been investigated.

Evidence continues to be largely animal-based, with a lack of human clinical data to establish treatment efficacy.

BPC-157 vs TB-500

BPC-157 and [TB-500](/peptides/tb-500) are both investigated in tissue-repair research, but they represent different peptide systems.

CompoundMain structural featureLengthKey distinction
Peptide originSynthetic pentadecapeptideThymosin β4-derived fragment
Length15 amino acids7 amino acids
Research focusTissue, vascular and gastrointestinal modelsWound healing, angiogenesis and tissue repair
Evidence basePredominantly preclinicalPredominantly preclinical
Human evidenceLimitedLimited

BPC-157 Safety and Regulatory Status

BPC-157 is an investigational peptide and is not FDA-approved. The FDA has reported limited safety information and raised concerns involving immunogenicity, peptide-related impurities and API characterization.

Current research therefore does not establish a well-characterized human safety profile or support routine clinical use.

WADA Status of BPC-157

BPC-157 is not currently listed as a prohibited substance by WADA, although it was temporarily prohibited in 2022.

Research reference note

Compare BPC-157 Research Materials

[Peptide Grading](#vendor-listings) helps compare BPC-157 suppliers, quantities, [COAs](/coas), specifications, shipping details, and price per mg in one place.

FAQ

Frequently asked questions.

BPC-157 is described in the literature as a peptide associated with gastric tissue and gastric juice.